Lilei Zhang, M.D., Ph.D.
Picture
Positions
- Associate Professor
-
Molecular and Human Genetics
草榴社区入口
Houston, TX US
- Associate Professor
-
Internal Medicine
草榴社区入口
- Associate Professor
-
Molecular Physiology and Biophysics
草榴社区入口
- Faculty Member
-
Genetics & Genomics Graduate Program
草榴社区入口
- Faculty Member
-
Development, Disease Models, & Therapeutics Graduate Program
草榴社区入口
Addresses
- BCM-MD Anderson Hall (Office)
-
Room: BCMA-441E
Houston, TX 77030
United States
Phone: (713) 798-2285
Education
- MD from Peking University Health Science Center
- 07/2001 - Beijing, China
- PhD from Johns Hopkins University
- 05/2006 - Baltimore, Maryland
- Human Genetics and Molecular Biology
- Postdoctoral Fellowship at Johns Hopkins University
- 05/2008 - Baltimore, Maryland
- Internship at University Hospitals Case Medical Center
- 06/2009 - Cleveland, Ohio
- Internal Medicine
- Residency at University Hospitals Case Medical Center
- 06/2012 - Cleveland, Ohio
- Internal Medicine
- Fellowship at University Hospital Case Medical Center
- 07/2013 - Cleveland, Ohio
- Medical Genetics
- Postdoctoral Fellowship at Case Western Reserve University
- 08/2016 - Cleveland, Ohio
Certifications
- Texas Medical Board
- Ohio Medical Board
- American Board of Medical Genetics and Genomics
- American Board of Internal Medicine
Professional Interests
- Genetic and Epigenetic regulation of heart failure and cardiomyopathies
- Investigate the pathogenesis and treatment for inherited cardiac diseases using iPSC-CM model
Professional Statement
Our overarching mission is to translate the study of genetic and epigenetic regulation of cardiovascular disease into novel therapeutic approaches. One of our research focuses is circadian gene regulation in cardiac remodeling. Our work covers the entire circadian regulatory landscape, from the core clock to the slave clock, to the effectors. We discovered that core clock factor REV-ERB is protective for cardiac pathological remodeling and pharmacological activation of REV-ERB prevents heart failure progression even in late-stages. We recently expanded this finding to both HFrEF and HFpEF models and mechanistically demonstrated that REV-ERB suppressed aberrant gene expression, which is required for heart failure development and progression. This was the first example of treating heart failure by manipulating circadian machineries and shows great promise to complement current standard of care. Our finding is now being accelerated towards IND. We also established the very first cardiac slave clock, KLF15, which controls the circadian ischemia reperfusion injury in the heart via regulating NAD+.Another focus of our laboratory is to study inherited cardiac diseases using induced pluripotent stem cell differentiated cardiomyocyte (iPSC-CM) model. We have recently demonstrated that folate can terminate otherwise lethal and recalcitrant arrhythmia in patients with TANGO2 deficiency disorder. This result corroborates what we have observed in large patient cohort and isolated case reports. Additionally, we use iPSC-CMs combined with genome editing, a battery of high throughput phenotyping and machine learning tools to answer human genetics questions in inherited cardiac diseases, including identifying novel disease genes, interpreting variants, understanding disease mechanisms, and testing novel therapeutic strategies.
Selected Publications
- Xu W, Cao Y, Stephens SB, Arredondo MJ, Chen Y, Perez W, Sun L, Yu AC, Kim JJ, Lalani SR, Li N, Horrigan FT, Altamirano F, Wehrens XH, Miyake CY, Zhang L "." JCI Insight. 2024 Jun 10;9:e171005. Pubmed PMID:
- Miyake CY, Mackenzie SJ, Zhang L "." Heart Rhythm. 2024;21:707-709. Pubmed PMID:
- Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K, Losby M, Hampton CS, Adeyemi CM, Hong SJ, Nasiotis E, Fu C, Oh TG, Fan W, Downes M, Welch RD, Evans RM, Milosavljevic A, Walker JK, Jensen BC, Pei L, Burris T, Zhang L. "." Circulation. 2024 Nov 14;149(3):227-250. Pubmed PMID:
- Le Li , Hui Li , Chih-Liang Tien , Mukesh K. Jain , Lilei Zhang "." Circulation. 2020 Apr 27;141(17):1427-1429. Pubmed PMID:
- Xu W, Li L, Zhang L "NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death.." Front Physiol.. 2020;11:901.
- Zhang L*, Zhang R, Tien CL, Chan RE, Sugi K, Fu C, Griffin AC, Shen Y, Burris TP, Liao X, Jain MK* "." JCI Insight. 2017;2(17):e95177. Pubmed PMID:
- Hsieh PN, Zhang L, Jain MK "." Cell Mol Life Sci.. 2017;75(3):403-416. Pubmed PMID:
- Zhang L, Jain MK "." PNAS. 2016 Mar 8;113:2558-9. Pubmed PMID:
- Zhang L, Prosdocimo DA, Bai X, Campbell F, Liao X, Coller J, Jain MK "." Cell Rep. 2015;13:2368-75. Pubmed PMID:
- Zhang L, Sabeh MK, Jain MK "Circadian rhythm and cardiovascular disorders." Chronophysiology and Therapy. 2014 Jul;2014:27-40.
- Xu W, Graves A, Weisz-Hubshman M, Hegazy L, Magyar C, Liu Z, Nasiotis E, Samee MAH, Burris T, Lalani S, Zhang L. "." Hum Mol Genet. 2023 Mar 6; Pubmed PMID:
- Miyake CY, Lay EJ, ..., Lalani SR, Zhang L. "." Heart Rhythm. 2022 Oct; Pubmed PMID:
- Zhang L, Jain MK. "." J Clin Invest.. 2021 Aug 2; Pubmed PMID:
- Hsieh PN, Zhang L, Jain MK. "." Cell Mol Life Sci.. 2018 Feb; Pubmed PMID:
- Song S, Tien CL, Cui H, Basil P, Zhu N, Gong Y, Li W, Li H, Fan Q, Min Choi J, Luo W, Xue Y, Cao R, Zhou W, Ortiz AR, Stork B, Mundra V, Putluri N, York B, Chu M, Chang J, Yun Jung S, Xie L, Song J, Zhang L, Sun Z. "." Circulation. 2022 Feb 8; Pubmed PMID:
- Zhang R, Shen Y, Zhou L, Sangwung P, Fujioka H, Zhang L, Liao X. "." J Mol Cell Cardiol.. 2017 Nov; Pubmed PMID:
to edit your profile
